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DOES ALLOGENEIC HSCT PLAY A ROLE IN FIRST-LINE POST-REMISSION
THERAPY FOR AML PATIENTSWITH T(8;21) IN FIRST COMPLETE REMIS-
SION?
Zhu, H.-H., Zhang, X.-H., Jiang, H., Liu, D.-H., Chen, H., Jiang, Q.,
Xu, L.-P., Lu, J., Han, W., Bao, L., Wang, Y., Chen, Y.-H., Lu, X.-J.,
Wang, J.-Z.,Wang, F.-R., Qin, Y.-Z., Lai, Y.-Y., Liu, R.-R., Liu, K.-Y.,
Jiang, B., Huang, X.-J. Peking University People’s Hospital, Peking Uni-
versity Institute of Hematology, Beijing Key Laboratory of Hematopoietic
Stem Cell Transplantation, Beijing, China
Whether allogeneic hematopoietic stem-cell transplantation (allo-
HSCT) can improve the outcome of high-risk relapse(HR) acute
myeloid leukemia(AML) patients with t(8;21) in first complete re-
mission (CR1) is still unknown. 76 patients with t(8;21)AML in
CR1 were analyzed. Post-remission treatment included chemother-
apy alone(n 5 35) and allo-HSCT(n 5 41). The minimal residual
disease (MRD) was monitored using quantitative PCR to detect
the RUNX1/RUNX1T1 transcript level. HR was defined as either
a RUNX1/RUNX1T1 transcript level that was continuously higher
than 0.1% or a transcript level that increased by more than one log
unit within 6 months since CR; all other patients were defined as
low-risk relapse (LR). A multivariate analysis of the total population
revealed that the post-remission treatment choice (chemotherapy or
allo-HSCT) and MRD status (LR or HR) were independent prog-
nostic factors for relapse.Allo-HSCTdecreased the relapse risk com-
pared to chemotherapy (cumulative incidence of relapse, CIR,
20.066.9% vs. 57.369.2%; p 5 0.0015), although neither the dis-
ease-free survival (DFS, 61.767.9% vs. 42.769.2%; p 5 0.09) nor
overall survival (OS, 68.067.8% vs. 52.5611.0%; p 5 0.40) were
significantly different. For the MRD-LR patients, allo-HSCT did
not improve outcome compared to chemotherapy (CIR, p 5 0.07;
DFS, p 5 0.57; OS, p 5 0.52). However, allo-HSCT significantly
improved the outcome of HR patients compared to chemotherapy
(CIR, 27.069.6% vs. 89.569.4%, p 5 0.0003; DFS, 55.7610.0%
vs. 10.569.4%, p 5 0.0099; OS, 67.869.4% vs. 14.2612.1%, p 5
0.046).HSCT can improve the outcome of HR patients with
t(8;21) in CR1 and should be considered an option for first-line
post-remission AML treatment.
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TARGETING MEMORY T CELLS WITH ALEFACEPT TO ABROGATE TRANS-
FUSION ALLOIMMUNIZATION: PRELIMINARY RESULTS FROM A TRIAL OF
REDUCED INTENSITY CONDITIONING AND ALLOGENEIC TRANSPLANT
FOR CHILDREN WITH NON-MALIGNANT HEMATOLOGIC DISEASES
Horan, J.T.1, Qayed, M.1, Haight, A.1, Couture, C.2, Chiang, K.Y.1,
Kean, L.1 1Emory University; 2Children’s Healthcare of Atlanta
Blood product transfusion related alloimmunization is a potent
barrier to engraftment of allogeneic hematopoietic stem cells in
non-malignant diseases (NMD). Memory T cells, which drive al-
loimmunization, are relatively resistant to commonly used condi-
tioning agents. We are conducting a trial for multiply transfused
childrenwithNMD, using alefacept, a recombinant LFA-3/IgG1 fu-
sion protein that depletes memory T cells by targeting CD2.We re-
port our experience in the first two patients. Both received five 0.5
mg/kg IV doses of alefacept on days -40, -33, -26, -19 and -12.
The first, a 2 year old, Asian-American with dyskeratosis congenital
and aplastic anemia (AA), then received five 25 mg/m2 daily doses of
IV fludarabine (FLU, days -6 through -2), one 50 mg/kg IV dose of
cyclophosphamide (CY,-2), one 200 cGy dose of total body irradia-
tion (-1) and a 5/6 HLAmatched unrelated cord blood unit (UCBT,
7.6 X 105 CD34+ cells/kg). The second, a 10 year old, African-
American with Fanconi anemia and AA, then received six 25 mg/
m2 daily doses of FLU (days -10 through -5), four 10mg/kg doses
of CY (-5 through -2) and a 5/6 HLA matched UCBT (2.1 X 105
CD34+ cells/kg). In both, rapid neutrophil recovery and full donorengraftment occurred. Alefacept infusions were well tolerated. The
first patient, 9 months post-transplant, has had several transplant re-
lated complications, including grade 3 acute GVHD and chronic
GVHD. The second, 6 months post-transplant, developed grade 2
acute GVHD and chronic GVHD, but is now tapering immune sup-
pression. We performed peripheral blood flow cytometry prior to
the first and following the last alefacept infusion (just prior to the
first fludarabine dose). During this period both patients demon-
strated loss of CD2high/CCR7-/CD45RA- effector memory
(Tem) and CD2high/CCR7+/CD45RA- central memory (Tcm)
CD4+ and CD8+ T cells with relative preservation of the CD2low
Tem and Tcm subpopulations. In Patient 1, there was a 2.1 and
1.6-fold decrease in CD4+CD2high Tem and Tcm, and a 9.6 and
1.3-fold decrease in CD8+ CD2high Tem and Tcm. In patient 2,
there was a 3.2 and 5.7-fold decrease in CD4+CD2high Tem and
Tcm, and a 4.4 and 19.7-fold decrease in CD8+ CD2high Tem
and Tcm. The preliminary results of our ongoing trial suggest that
alefacept may hold promise as a conditioning agent for alloimmu-
nized patients. Continued research is needed to define alefacept’s
safety and efficacy and elucidate its biologic effects in this setting.326
DOSE, SCHEDULE AND PK PRACTICES WITH IV BUSULFAN-BASED CON-
DITIONING REGIMENS IN A NON-INFERIORITY STUDY: HETEROGENOUS
PRACTICES BUT LOW VOD AND TRM
Bredeson, C.1, Burkart, J.2, Sun, Y.3, Zhu, X.2, LeRademacher, J.2,
Rizzo, J.D.2, Armstrong, E.3, Pasquini, M.2, Kato, K.3 1The OttawaHos-
pital, Ottawa, ON, Canada; 2CIBMTR, Medical College of Wisconsin,
Milwaukee, WI; 3Otsuka Pharmaceutical Development & Commercialia-
tion, Inc., Princeton, NJ
TheCIBMTR is conducting a non-inferiority study of myeloabla-
tive IV busulfan-based conditioning regimens vs. traditional ablative
cyclophosphamide and TBI in patients (pts) with myeloid malignan-
cies undergoing related or unrelated SCT to compare overall sur-
vival between regimens. Accrual is complete with 477 pts
conditioned with CyTBI and 1273 with IV busulfan-based regimens
from 120 centers. We report initial data regarding busulfan (BU)
dosing and PK practices. Of 1273 pts receiving IV BU, the regimen
was ablative in 1118 and reduced intensity in 155. Donors were re-
lated (507 pts) or unrelated (766 pts). Diagnosis was AML (791
pts), MDS (365 pts), CML (117 pts). Graft source was BM (272
pts) or PB (1001 pts). Median age was 47 (1-61) yrs and 52% of
pts were male. The majority (66%) had a performance score of 90-
100. GVHD prophylaxis for all pts was a calcineurin inhibitor of ta-
crolimus (1035 pts) or cyclosporine (238 pts) +/- other agents. BU
dosing was most commonly Q6H followed by daily. The vast major-
ity of pts received 4 days of BU (95%), including about half of the
RIC group. Approximately half of both related and unrelated SCT
recipients underwent PK testing. Most PK testing was done with
the first dose of conditioning (80.6%), the remainder as a preceding
test dose. Dose adjustment was planned for nearly all pts receiving
ablative regimens that underwent PK testing (98%) and in aminority
of RIC pts (8%). BU was targeted based on AUC in 63.5%; the re-
mainder with CSS. Some centers used both AUC and CSS for PK
testing. Most pts’ subsequent BU dose (77.6%) was adjusted in re-
sponse to PK results including 5 RIC pts. The incidence of VOD
at 100 days for all pts receiving IV busulfan-based conditioning
was 5% (4%-7%) and was similar in pts receiving ablative or RIC.
In 889 pts with data available, the cumulative incidence of TRM at
100 days and 6 months was 8% (6%-10%) and 12% (10%-14%).
Practices regarding BU dosing and schedules and the use of PK test-
ing with IV busulfan-based conditioning vary within and between
centers. In a large prospective observational study, IV busulfan-
based conditioning regimens appear safe with a low incidence of
VOD and TRM in a group of pts receiving both related and unre-
lated transplants. Results from the comparative study after 1 year
of follow up will address the safety and efficacy of IV busulfan-based
conditioning regimens compared to CyTBI.S325
